Recent clinical trials of cancer gene therapy have shown encouraging results for controlling localized tumors. However, to control metastatic or disseminated tumor cells, further modification of vectors is required to enhance specificity and infectivity against targets. We investigated whether utili
HSVTK gene therapy for carcinoembryonic antigen-producing human lung cancer cells
β Scribed by Xiao Geng-fu; Qi Yi-peng; Cheng Xuan-hong; Li Ling-yun
- Publisher
- Wuhan University
- Year
- 1999
- Tongue
- English
- Weight
- 608 KB
- Volume
- 4
- Category
- Article
- ISSN
- 1007-1202
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract ## Background Mesenchymal stem cells (MSCs) are a promising vehicle for targeted cancer gene therapy because of their potential of tumor tropism. For efficient therapeutic application, we developed retroviral vectorβproducing MSCs that enhance tumor transduction via progeny vector prod
Recent clinical trials of gene therapy for patients with thoracic cancers have shown that these treatments were well tolerated with minimal side effects and that we need to further enhance specificity as well as efficiency of gene transfer to target cancer cells. We previously reported that mycovere
lacZ gene driven by the b-actin -based promoter. Ex-SEE EDITORIAL ON PAGE 1696. pression of the HSVtk gene by adenovirus from AFP promoter/enhancer (AdAFPtk) induced the cells sensitive to ganciclovir (GCV) in the AFP-producing cell We have developed a recombinant replication-deline efficiently, but